Patients with advanced cancer often face difficult choices and heavy symptom burdens. This study looked at whether a simple change in how care is delivered could make a difference. The researchers focused on patients referred for radiotherapy to treat painful bone metastases. These are spots where cancer has spread to the bones, causing real physical distress. The team compared two groups. One group received a consultation with the hospital palliative care consultation team. The other group received usual care without knowing about the trial. The main goal was to see if patients felt more satisfied with their care. They also checked symptom burden, quality of life, and overall survival. The study followed patients for four weeks. No safety issues or discontinuations were reported because the intervention was a consultation, not a drug. The results are not yet fully reported in this protocol, but the setup aims to show if specialist support helps. This research may provide evidence to support timely integration of specialist palliative care for all patients with bone metastases who may benefit from specialist palliative care.
Palliative care consultation for bone metastases radiotherapy patients shows no outcome data in protocolHospital palliative care teams may improve satisfaction for advanced cancer patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This study protocol describes a randomized controlled trial in 246 patients referred for hospital radiotherapy for symptomatic bone metastases from advanced cancer. The intervention is consultation with the hospital palliative care consultation team, compared to usual care where the control group was not informed about the trial. The primary outcome is patient satisfaction with care, measured with the EORTC PATSAT-C33 questionnaire at four weeks. Secondary outcomes include symptom burden, quality of life, overall survival, palliative care utilization, and patient experiences with the consultation. No main results are reported in this protocol. Adverse events, serious adverse events, discontinuations, and tolerability are not reported. Key limitations include the lack of reported results and the fact that this is only a protocol. The practice relevance suggests this may provide evidence to support timely integration of specialist palliative care for patients with bone metastases who may benefit, but findings are not yet available.